Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2424726 | 0.92 | BRAF (1.00) | BRAF | |
| SCHEMBL24592540 | 0.90 | BRAF (0.81) | BRAF | |
| SCHEMBL29800262 | 0.90 | BRAF (0.81) | BRAF | |
| SCHEMBL23057000 | 0.88 | BRAF (0.79) | BRAFRAF1 | |
| SCHEMBL23057316 | 0.88 | BRAF (0.78) | BRAFRAF1 | |
| SCHEMBL23057201 | 0.87 | BRAF (0.77) | BRAFRAF1 | |
| SCHEMBL15124467 | 0.86 | BRAF (1.00) | BRAF | |
| SCHEMBL24592450 | 0.86 | BRAF (0.75) | BRAFRAF1 | |
| SCHEMBL24592471 | 0.85 | BRAF (0.86) | BRAF | |
| SCHEMBL12465275 | 0.84 | BRAF (0.72) | BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290507-B2 | B-RAF kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-22 | — | — | US | claimed |
| EP-2552905-A1 | B-RAF KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2013-02-06 | — | — | EP | claimed |
| WO-2011117381-A1 | B-RAF KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-29 | — | — | WO | claimed |
| EP-4023643-A1 | PYRAZOLE DERIVATIVE AND USE THEREOF | Hefei Institutes of Physical Science, Chinese Academy of Sciences (CN) | 2022-07-06 | — | — | EP | disclosed |
| EP-2552905-B1 | B-Raf kinase inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-9290507-B2 | B-RAF kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-22 | — | — | US | disclosed |
| US-20130190286-A1 | B-RAF KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| WO-2011117381-A1 | B-RAF KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190286-A1 | B-RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.